Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing
Autor: | Vamshi Muddu, T. P. Sahoo, Bivas Biswas, Mithua Ghosh, Ashok K. Vaid, Suresh H. Advani, Ullas Batra, Anuradha Chougule, Kumar Prabhash |
---|---|
Rok vydání: | 2019 |
Předmět: |
Oncology
030213 general clinical medicine medicine.medical_specialty biology Molecular screening business.industry General Medicine Guideline Checklist 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Health care biology.protein medicine Biomarker (medicine) Anaplastic lymphoma kinase Pharmacology (medical) Epidermal growth factor receptor Non small cell business |
Zdroj: | Advances in Therapy. 36:766-785 |
ISSN: | 1865-8652 0741-238X |
DOI: | 10.1007/s12325-019-00903-y |
Popis: | Novel molecular targets and promising targeted therapies have reshaped diagnostics in patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the implementation of molecular screening to identify predictive biomarkers in Indian clinical and pathology settings has been challenging due to operational and logistical constraints. This consensus guideline brings together medical oncologists, molecular pathologists and pathologists from India to provide a quick and competent reference for biomarker testing in NSCLC. The guideline summarizes the importance of targetable mutations in NSCLC such as epidermal growth factor receptor (EGFR), rearrangements in anaplastic lymphoma kinase and receptor tyrosine kinase encoded by ROS-1 gene, overexpression of programmed cell death ligand-1 and resistant EGFR mutations. It reaffirms recommendations from international working groups, discusses vulnerable pre-analytical procedures and provides a balanced review on the pros and cons of different diagnostic tests (immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction-based testing and next-generation sequencing). The document also provides an algorithm to aid diagnostic decision-making and a checklist to assess the quality of testing laboratories that will help the medical oncologists make an informed choice. Overall, these recommendations are based on evidence and clinical experience and will aid policymakers, oncologists, health care practitioners and pathologists who strive to implement molecular strategies and make informed decisions for improved care in NSCLC in India.Funding: AstraZeneca Pharma India Limited. |
Databáze: | OpenAIRE |
Externí odkaz: |